

**Date and Time:** **19 July 2013, 1000 - 1600**

**Minutes:** Confirmed

**Guideline Development Group Meeting 5**

**Place:** *National Clinical Guidelines Centre,  
180 Great Portland Street, London, W1W 5QZ*

**Present:**

**GDG**  
 Shuaib Nasser(Chair) (SN)  
 Andrew Williams (AW)  
 David Cousins (DC)  
 George Du Toit (GDT)  
 James Larcombe (JL)  
 Mandy East (ME)  
 Mike Arden-Jones (MAJ)  
 Nicola Mundy (NM)  
 Pamela Ewan (PE)

**NCGC**  
 Carlos Sharpin (CS)  
 Gill Ritchie (GR)  
 Kathy De Mott (KDM)  
 Martin Harker (MH)  
 Tamara Diaz (TD)

**Apologies:**  
 Alice Osborne (AO)  
 Paul Whitaker (PW)  
 Grace Marsden (GM)

**In attendance:**

NICE Staff:	Caroline Keir (CK)	
-------------	--------------------	--

**Observers:**

NICE/NCGC Staff:	None	
------------------	------	--

## Notes

1. Welcome and Declarations of Interest: SN welcomed the group to the fifth meeting of this GDG. Formal apologies were heard from AO and PW. The Chair asked all GDG members to declare any relevant conflicts of interest.

The following declarations of interests were heard from the group, but none were found to be relevant to the day's agenda therefore no further action was required for this meeting. All GDG members declaring interests were asked to submit completed, signed forms by the end of the meeting:

- a. Since the last meeting the chair advised that he had been sponsored to attend an allergy conference by CSL Behring in June 2013. Sponsorship comprised of registration and accommodation. Reasonable expenses to attend conferences does not constitute a conflict of interest but was declared for the information of the group.
- b. GDT advised that Thermofisher supports two food allergy studies that he is currently involved in. The testing kits supplied by the company relate to food allergy, not drug allergy, however this company does produce ImmunoCap tests for drug allergy, and was recorded as a non-personal pecuniary interest.
- c. MD advised that he had been recently paid £500 for writing an article on Allergic Rhinitis for the Guidelines in Practice magazine and this was recorded as a personal pecuniary interest.

All other GDG members declared that they knew of no personal specific, personal non-specific, non-personal specific or non-personal non-specific interests that would present conflicts in the development of this guideline.

2. Confirmation of the Minutes of GDG 4: The GDG confirmed the accuracy of the circulated minutes.
3. Evidence Review: The GDG heard evidence related to the following clinical questions: What is the clinical and cost effectiveness of clinical probability scores or algorithms in identifying or excluding drug allergies?
4. Review Protocols: Review protocols were finalised for the following clinical areas:
  - a. Management COX 2
  - b. Documentation
5. Close of business: There being no further business the meeting ended at 4:00 p.m.

### **Date, time and venue of the next meeting**

6. Monday 3 September 2013, 1000 to 1600 at the National Clinical Guidelines Centre, 180 Great Portland Street, London, W1W 5QZ.